MAP4K4 and lung adenocarcinoma: Current evidence indicates that MAP4K4 can potentially serve as a negative prognostic indicator in patients with colorectal cancer (CRC) [30], hepatocellular carcinoma (HCC) [31], pancreatic ductal adenocarcinoma (PDAC) [32], lung adenocarcinoma [33] and prostate cancer [34].